ABPI, re­searchers crit­i­cize NHS’ In­no­v­a­tive Med­i­cines Fund, with no new ther­a­pies avail­able over a year af­ter for­ma­tion

Two years ago, the UK’s Na­tion­al Health Ser­vice an­nounced the cre­ation of the In­no­v­a­tive Med­i­cines Fund (IMF), de­signed to cov­er the cost of new rare dis­ease drugs that don’t yet have enough da­ta to sat­is­fy the gov­ern­ment’s pric­ing watch­dog NICE, but might still of­fer some ben­e­fit for pa­tients.

But no new med­i­cines have been made avail­able yet through the fund, and re­searchers and in­dus­try stake­hold­ers have brought their crit­i­cisms and rec­om­mend­ed changes to light.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER